Therapy development for adult diffuse glioma is hindered by incomplete knowledge of somatic
glioma driving alterations and suboptimal disease classification. We defined the complete …

The factors driving therapy resistance in diffuse glioma remain poorly understood. To
identify treatment-associated cellular and genetic changes, we analyzed RNA and/or DNA …

We present a proteogenomic study of 108 human papilloma virus (HPV)-negative head and
neck squamous cell carcinomas (HNSCCs). Proteomic analysis systematically catalogs …

Glioblastoma (GBM) is the most aggressive nervous system cancer. Understanding its
molecular pathogenesis is crucial to improving diagnosis and treatment. Integrated analysis of …

Biotechnological advances in sequencing have led to an explosion of publicly available
data via large international consortia such as The Cancer Genome Atlas (TCGA), The …

The transcriptomic classification of glioblastoma (GBM) has failed to predict survival and
therapeutic vulnerabilities. A computational approach for unbiased identification of core …

Neurofibromatosis type 1 (NF1) is a common tumor predisposition syndrome in which glioma
is one of the prevalent tumors. Gliomagenesis in NF1 results in a heterogeneous spectrum …

Despite producing a panoply of potential cancer-specific targets, the proteogenomic
characterization of human tumors has yet to demonstrate value for precision cancer medicine. …

Sampling restrictions have hindered the comprehensive study of invasive non-enhancing (NE)
high-grade glioma (HGG) cell populations driving tumor progression. Here, we present …

The evolutionary trajectory of glioblastoma (GBM) is a multifaceted biological process that
extends beyond genetic alterations alone. Here, we perform an integrative proteogenomic …